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Background: Obesity is a growing worldwide epidemic. There is association between obesity and
pancreatic cancer risk. However, the impact of obesity on the outcome of pancreatoduodenectomy (PD)
is controversial. The aim of this study was to elucidate effect of obesity on surgical outcomes of PD.
Study design: A case-control study.
Patient and methods: We retrospectively studied all patients who underwent PD in our center between
January 2000 and June 2012. Patients were divided into two groups; Group A (patients with BMI <25)
and Group B (patients with BMI > 25). Preoperative demographic data, intraoperative data, and post-
operative details were collected.
Results: Only 112/471 patients (25.9%) had BMI > 25. The median intraoperative blood loss was more in
overweight patients (P ¼ 0.06). The median surgical time in group B was signiﬁcantly longer than that in
groupA (P¼ 0.003). The overall incidence of complicationswas higher in the overweight group (P¼ 0.001).
The severity of complications was also higher in the overweight group (P ¼ 0.0001). Postoperative
pancreatic ﬁstula (POPF) (P ¼ 0.0001) and hospital mortality (P ¼ 0.001) were signiﬁcantly higher in
overweight patients. Oral intakewas signiﬁcantly delayed in overweight patients in comparison to normal
weight group (P ¼ 0.02). Postoperative stay was signiﬁcantly longer in overweight patients (P ¼ 0.0001).
Conclusion: PD is associated with an increased risk of postoperative morbidity in overweight patient.
Overweight patients must not be precluded from undergoing PD. However, operative techniques and
pharmacological prophylaxis to decrease POPF should be considered in overweight patients.
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Pancreaticoduodenectomy (PD) is the standard treatment for a
wide array of periampullary and pancreatic diseases including
malignant and benign conditions [1]. PD is widely performed for
management of periampullary malignancy [2]. The outcome of PD
has improved over the past two decades due to advances in surgical
techniques, anesthesia and perioperative care [3]. Although reports
from high volume centers demonstrate decline in the operative
mortality to less than 3%, the postoperative morbidity rate is still
ranging from 20% to 60% [4e10].
Obesity is a growing worldwide epidemic [11]. Obesity is
established as a risk factor for several diseases diabetes, hyper-
tension, coronary heart diseases, gall bladder diseases, sleep apnea(mobile), þ20 0502353430
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ciates Ltd. Published by Elsevier Ltand osteoarthritis [12]. It has also been linked to development of
malignancy occurring in the colon, uterus, ovary, kidney and other
organs [13]. Obesity is also thought to affect the outcome of the
surgical management of gastrointestinal malignancies as gastric
and colorectal cancers [14,15].
There is cumulative evidence supporting the association be-
tween obesity and pancreatic cancer risk [16]. However, the impact
of obesity on the outcome of PD is controversial and not well-
studied [17,18]. Available studies displayed conﬂicting results
regarding the impact of obesity on morbidity and mortality
following PD [18]. The purpose of this research is to show the clinical
impact of obesity on the outcome of PD for periampullary lesions.
2. Patients and methods
2.1. Patients
This is a retrospective analysis of all patients who underwent PD in the duration
between January 2000 and June 2012 in Gastrointestinal Surgical Center, Mansoura
University, Egypt. The indications for PD were malignant periampullary tumors,
pancreatitis, solid pseudopapillary tumors and neuroendocrinal tumors. Wed. All rights reserved.
Table 1
Demographic data.
Variables BMI <25 BMI >25 P values
Age
Median age (years) 53 (12e79) 54 (24e80) 0.38
<60 years 278 (77.4%) 79 (70.5%) 0.16
>60 years 81 (22.6%) 33 (29.5%)
Sex
Female 213 (59.3%) 65 (58%) 0.82
Male 146 (40.7%) 47 (4%)
Symptoms
Jaundice 329 (91.6%) 102 (91.1%) 0.84
Abdominal pain 265 (73.8%) 74 (66.1%) 0.11
Median preoperative albumin (gm%) 3.9 (3.2e5) 4 (3.4e5) 0.73
Median preoperative bilirubin (mg%) 4.7 (0.5e38) 6.5 (0.6e37) 0.3
Preoperative biliary drainage (ERCP) 189 (52.6%) 61 (54.5%) 0.75
Preoperative CEA
Median (ng/m) 12 (20e394) 12 (0.5e322) 0.14
Preoperative CA19-9
Median (U/ml) 26 (20e1061) 28 (0.5e1080) 0.32
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serving PD for the sake of homogeneity of the patients.
For this a case-control study, patients were divided into two groups based on
BMI: group A (None obese group, patients with BMI > 25) and group B (overweight
group, patients with BMI  25).
Patient data were recorded in a prospectively maintained database for all pa-
tients undergoing pancreatic surgery since 2000. Collected data included patient
demographics, preoperative laboratory investigation, preoperative tumor markers,
operative details, duration of hospital stay, pathological features of the resected
tumor and postoperative morbidity and mortality.
2.2. Operative
Standard PD was performed after mobilizing the pancreatic head, uncinate
process and the duodenum, the pancreas was divided anterior and to the left of
superior mesentric vein (SMV) and portal vein (PV). All patients underwent regional
lymphadenectomy, which included resection of nodes within the outline of celeic,
superior mesentric artery (SMA) and all tissues in hepatoduodenal ligaments. The
presence of obesity did not modify the standard procedure.
Pancreatic reconstruction was done by pancreaticogastrostomy (PG) or pan-
creaticojejunostomy (PJ) according to surgeon’s preference. Biliary drainage was
achieved by retrocolic end to side hepaticojejunostomy. Gastric drainage was done
by antecolic gastrojejunostomy (GJ) which was performed manually.
All operative pathologic specimens were reviewed to determine tumor size,
tumor differentiation, lymph node status, surgical safety margins, perineural and
perivascular invasion. The safety margin is marked by the surgeon (lower end CBD,
pancreatic neck, mesopancreas, uncinate process). Surgical safety margins were
considered inﬁltrated when the malignant cells were present at any of the cut
margins.
2.3. Postoperative management
All patients were managed in the intensive care unit for at least one day. All
patients received prophylactic antibiotics intraoperatively and for 4 days post-
operatively. We routinely refer our patients for postoperative chemotherapy in the
last 3 years.
We adopted the classiﬁcation system of postoperative complication proposed by
Dindo and colleagues [19] and Clavien and colleagues [20]. According to this system,
grades I (no need for speciﬁc intervention), grade II (need for drug therapy such as
antibiotics, blood transfusion, total parentral nutrition), grade IIIa-b (need for
invasive therapy whether radiological, endoscopic or surgical), grade IVa-b (organ
dysfunction requiring ICU stay and management), grade V (death). Grades I to IIIa
complications were considered minor, while grades IIIb to V were considered major
complications. In patients who experienced more than one complication, we chose
the highest grade complication for the purpose of comparison between the groups.
2.4. Assessments
The primary outcome was the rate of postoperative pancreatic ﬁstula (POPF).
POPF was deﬁned by International Study Group of Pancreatic Fistula (ISGPF) as any
measurable volume of ﬂuid on or after POD 3 with amylase content greater than 3
times the serum amylase activity [21]. The severity of POPF was assessed using
Dindo-Clavien complication classiﬁcation system. POPF was graded according to
the International Study Group of Pancreatic Fistula criteria into Grade A, B, and C
according to the clinical course [21].
Secondary outcomes were total operative time, operative time needed for
reconstruction, length of postoperative stay, postoperative complications including
(delayed gastric emptying, biliary leakage, bleeding PG, bleeding GJ, internal
hamorrhage, and pulmonary complications), re-exploration, and survival rate.
Delayed gastric emptying was deﬁned as output from a nasogastric tube of greater
than 500 ml per day that persisted beyond 10th POD, the failure to maintain oral
intake by 14th POD, or reinsertion of a nasogastric tube. Biliary leak was deﬁned as
the presence of bile in the drainage ﬂuid that persists to 4th POD [21,22].
Statistical analysis of the data in this study was performed using SPSS software,
version 17 (Chicago, IL). Descriptive data were expressed as means with standard
deviation or medians with ranges according to data distribution. Categorical vari-
ables were described using frequency distributions. Independent sample t-test was
used to detect differences in the means of continuous variables and Chiesquare test
was used in cases with low expected frequencies. P values <0.05 were considered
signiﬁcant.
3. Results
A total number of 471 cases underwent standard PD for resec-
tion of periampullary lesions in Gastrointestinal Surgical Center,
Mansoura University, Egypt. Group A (None obese group, patients
with BMI > 25) included 359 (74.1%) patients while group B(overweight group, patients with BMI  25) included 112 (25.9%)
patients. Both groups were comparable with no signiﬁcant differ-
ence between them as regard the patient demographics, preoper-
ative laboratory investigation, clinical presentation, serum level of
tumor markers, indication of resection and site of the lesion
(Table: 1).
There was no difference in pancreatic texture between both
groups. Although the median blood loss was more in overweight
group, it didn’t reach statistical signiﬁcance (P ¼ 0.06). There was a
statistically higher operative time in group B in comparison to
group A (P ¼ 0.003) (Table 2).
The median length of hospital stay after PD in overweight pa-
tients is (9 days) compared to (8 days) in non-obese patients
(P ¼ 0.0001). The median day to resume oral intake was signiﬁ-
cantly delayed in overweight patients (6 days) than in non-obese
patients (5 days) (P ¼ 0.02). The overall incidence of complica-
tions and its severity were higher in overweight group (P ¼ 0.001).
There was signiﬁcant difference in the incidence of POPF and its
severity (P ¼ 0.0001), delayed gastric emptying (P ¼ 0.008) and
pulmonary complication (P ¼ 0.04) in overweight group. Hospital
mortality is signiﬁcantly higher in overweight group (P ¼ 0.001)
(Table 3).
After pathological examination, there was no signiﬁcant differ-
ence between the two groups as regard the number of harvested
lymph nodes, number of inﬁltrated lymph nodes, lymph node ratio,
perivascular inﬁltration and perineural invasion. The safety margin
was signiﬁcantly inﬁltrated in the non-obese group in comparison
to the overweight group (P ¼ 0.02) (Tables 4 and 5).
4. Discussion
Despite the decline in operative mortality after PD to less than
3% inmost high volume centers, the rate of postoperativemorbidity
is approximately 40% [4e8]. Pancreatic surgeons are examining the
efﬁcacy of many strategies to decrease complications after PD.
These strategies include reﬁnements in surgical technique, phar-
macological prophylaxis and precise patient selection [23e26].
Obesity is reported to increase the technical difﬁculty of many
abdominal surgeries and this was translated into longer operative
time [27,28]. In this series, the operative time was signiﬁcantly
longer in the overweight group. William et al. reported that obesity
but not overweight was signiﬁcantly associated with longer oper-
ative time [2]. However, Shimizu et al. found that operative time
was signiﬁcantly correlated with BMI and visceral fat area
(P ¼ 0.0088 and P < 0.0001, respectively) [29]. This can be justiﬁed
Table 2
Operative data.
Variables BMI <25 BMI >25 P values
Mass size (cm)
Median mass size (cm) 3 (1e10) 3 (1e7) 0.43
2 cm 143 (39.8%) 40 (35.7%) 0.5
>2 cm 216 (60.2%) 72 (64.3%)
Pancreatic duct diameter
Median pancreatic duct
diameter (mm)
6 (1e15) 5.5 (1e12) 0.51
3 mm 100 (27.9%) 33 (29.5%) 0.81
>3 mm 259 (72.1%) 79 (70.5%)
Pancreatic consistency
Firm 235 (65.5%) 72 (64.3%) 0.82
Soft 124 (34.5%) 40 (35.7%)
Relation of pancreatic duct to the posterior border
Median (mm) 4 (1e6) 3 (1e5) 0.39
3 mm 167 (46.5%) 57 (50.9%) 0.44
>3 mm 192 (53.5%) 55 (49.1%)
Intraoperative blood loss (ml)
Median blood loss (ml) 320 (50e3000) 500 (100e2000) 0.06
<500 ml 198 (55.2%) 51 (45.5%) 0.08
>500 ml 161 (44.8%) 61 (54.5%)
Type of reconstruction
PG 321 (89.4%) 103 (92%) 0.66
PJ 38 (10.6%) 9 (8%)
Median total operative
time (hours)
5 (3e9) 5.35 (3.5e8) 0.003
Table 4
Postoperative pathology.
Variables BMI <25 BMI >25 P values
Site
Ampullary 122 (34%) 30 (26.8%) 0.25
Pancreatic head mass 203 (56.5%) 70 (62.5%)
Duodenal tumor 21 (5.8%) 10 (8.9%)
Lower CBD tumor 13 (3.6%) 2 (1.8%)
Indication of resection
Malignant 326 (90.8) 103 (84.4%) 0.69
Benign 26 (7.2%) 6 (5.4%)
Border line 7 (2%) 3 (2.7%)
Safety margin
R0 316 (88%) 107 (95.5%) 0.02
R1 40 (11.1%) 3 (2.7%)
R2 3 (0.8%) 2 (1.8%)
No of harvested node 6 (1e24) 6 (2e24) 0.17
No of LN metastasis 1 (0e12) 1 (0e8) 0.91
Lymph node ratio
No 209 (58.2%) 65 (58%) 0.06
<0.2 67 (18.7%) 12 (10.7%)
0.2e0.4 51 (14.2%) 17 (15.2%)
>0.4 32 (8.9%) 18 (16.1%)
Perivascular inﬁltration 40 (11.1%) 8 (7.1%) 0.28
Perineural inﬁltration 69 (19.2%) 19 (17%) 0.67
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consumption in safe handling of fatty tissues [30].
Operative blood loss is considered a quality indicator for pan-
creatoduodenectomy [6]. There was no signiﬁcant difference be-
tween normal and overweight groups regarding operative blood
loss or other operative events. Although unexpected, these resultsTable 3
Postoperative data.
Variables BMI <25 BMI >25 P values
Hospital stay (days) 8 (4e70) 9 (4e71) 0.0001
Drain removal (days) 8 (4e70) 8 (4e71) 0.007
Amount of draining (ml) 600
(40e15,000)
720
(75e35,000)
0.07
Time starting oral (days) 5 (4e56) 6 (4e46) 0.02
Total patients with
complications
62 (17.3%) 37 (33%) 0.001
Complications grade
I 10 (2.8%) 3 (2.7%) 0.0001
II 24 (6.7%) 13 (11.6%)
III 25 (7%) 13 (11.6%)
IV 0 0
V 3 (0.8%) 8 (7.1%)
Severe complications (IIIb)
Minor 34 (9.5%) 21 (18.8%) 0.001
Major 18 (5%) 16 (14.3%)
Postoperative pancreatic ﬁstula (POPF) 29 (8.1%) 28 (25%) 0.0001
Grade A 15 (4.2%) 6 (5.4%)
Grade B 10 (2.8%) 12(10.7%) 0.0001
Grade C 4 (1.1%) 10 (8.9%)
Pancreatitis 5 (1.4%) 2 (1.8%) 0.67
Biliary leakage 20 (5.6%) 7 (6.3%) 0.81
Delayed gastric
emptying
35 (9.7%) 22 (19.6%) 0.008
Bleeding GJ 9 (2.5%) 4 (3.6%) 0.51
Internal hemorrhage 8 (2.2%) 5 (4.5%) 0.2
Wound infection 22 (6.1%) 11 (9.8%) 0.2
Pulmonary complications 18 (5%) 12 (10.7%) 0.04
Re-exploration 27 (7.5%) 11 (9.8%) 0.43
Hospital mortality 3 (0.8%) 8 (7.1%) 0.001
Pulmonary embolism 1 2
SIRS 2 5
Liver insult 0 1were consistent with previous reports stating no signiﬁcant asso-
ciation between BMI and blood loss by Ito et al. (P ¼ 0.14) and
House et al. (P ¼ 0.6) [17,31]. Shimizu et al. reported signiﬁcant
association blood loss and visceral fat area (P ¼ 0.0008) but not
with BMI (P ¼ 0.0575) [29]. Williams et al. found signiﬁcant asso-
ciation between blood loss and obesity (P ¼ 0.04) but not in over-
weight patients (P ¼ 0.06) [2]. On the other hand, Benns et al. and
Tsai et al. found signiﬁcant association between operative blood
loss and BMI (P ¼ 0.0008, P ¼ <0.01 respectively) [30,32].
PD is a complex surgery that entails a long list of operative
complications. Previous studies on the relation between BMI and
postoperative complications showed conﬂicting results. Noun et al.
concluded that obesity doesn’t increase the risk of morbidity after
PD (P ¼ 1.0) [33]. In the current study, obesity is associated with
increased overall complication rate as well as increased severity of
the complications. Some studies corroborate our experience in the
increased likelihood of complications in obese patients [30,31]. In
general, this can be attributed to decreased performance status and
associated co-morbidities in obese and overweight patients [18].
Regarding speciﬁc complications, overweight was signiﬁcantly
associated with development of POPF, delayed gastric emptying
and pulmonary complication (P ¼ 0.0001, P ¼ 0.008, P ¼ 0.04
respectively). House et al. found increased likelihood of occurrence
of wound infection (P ¼ 0.03) while there was no increased risk of
any other complications in overweight patients (P ¼ 0.07) [17]. Tsai
et al. found increased likelihood of POPF in obese patients (P¼ 0.01)
with no increased risk of other complications (P ¼ 0.4) [32].
POPF is the most devastating complication following pan-
creatoduodenectomy. According to the current study, there is a
signiﬁcant association between the severity of POPF and over-
weight. This association is attributed in previous studies to the as-
sociation between soft pancreatic texture and obesity [2,30,32e35].
However, we found no signiﬁcant difference between overweight
and normal weight groups regarding pancreatic texture (P ¼ 0.82).
Similarly, Noun et al. found that BMIwas not signiﬁcantly associated
with occurrence of POPF (P ¼ 0.05) while it was signiﬁcantly asso-
ciated with increased intrapancreatic fat (P ¼ 0.001) which in turn
was signiﬁcantly associated with POPF (P ¼ 0.003) [33].
There was a signiﬁcant increase in the hospital stay in over-
weight patients in comparison to normal weight patients. Although
not a complication, longer hospital stay reﬂects the occurrence of
Table 5
Impact of obesity on surgical outcomes in recent series.
First author, year Sample size
(non-obese/obese
or overweight)
BMI Outcomes with BMI association
OR (range) P value
Outcomes without BMI association
OR (range) P value
Rosso et al. [36], 2009 111 (59/52) > <25 - Pancreatic ﬁstula (NR/0.035)
- Fatty pancreas (NR/0.0001)
Ito et al. [31], 2012 98 (70/28) > <25 - Pancreatic ﬁstula (NR/<0.05)
- Intra-abdominal collection (NR/<0.05)
- Pancreatic duct diameter (NR/0.13)
- Operative time (NR/0.75)
- Blood loss (NR/0.14)
- Blood transfusion (NR/0.59)
- Tumor size (NR/0.37)
- Lymph nodes (NR/0.84)
- Tumor stage (NR/0.4)
- Delayed gastric emptying (NR/0.51)
- Wound infection(NR/0.51)
- Intra-abdominal bleeding (NR/0.51)
- Respiratory insufﬁciency (NR/0.39)
- Sepsis (NR/0.53)
- Bile leakage (NR/0.53)
- Gastrointestinal bleeding (NR/0.11)
Shimizu et al. [29], 2011 317 (271/46) > <25 - Operative time (NR/0.0088)
- BMI (NR/0.0001)
- Blood loss (NR/0.0008)
- Red blood cell transfusion (NR/0.0276)
- Postoperative complications (NR/0.0434)
- Pulmonary complications (NR/0.0058)
- Mortality (NR/0.0143).
- Postoperative pancreatic ﬁstula (NR/0.282)
Su et al. [39], 2010 101 (89/12) > <25 Infectious complications (NR/0.002)
House et al. [17], 2008 356 > <30 - Wound infection (NR/0.03) - Operative time (NR/NR)
- Blood loss (NR/0.6)
- Any complication (NR/0.07)
- Pancreatic ﬁstula (NR/0.11)
Noun et al. [33], 2008 92 (73/19) > <30 - Increased intrapancreatic fat (NR/0.001)
which correlated positively with the
occurrence of pancreatic ﬁstula (P ¼ 0.003)
- Postoperative hospital stay (NR/0.015)
- Intraoperative blood transfusion (NR/1.0)
- Operative time (NR/0.2)
- Pancreatic ﬁstula (NR/0.05)
- Delayed gastric emptying (NR/0.7)
- Intra-abdominal abscess (NR/0.6)
- Wound infection (NR/0.6)
- Hemorrhage (NR/0.6)
- Re-operation (NR/0.5)
- Morbidity (NR/1.0)
- Mortality (NR/0.1)
Williams et al. [2], 2009 240 (174/66) > <30 - Prevalence of preoperative biliary
stent (NR/0.001)
- Intraoperative blood loss (2.00/0.02)
- Operative duration (2.39/0.005)
- Postoperative length of stay (1.9/0.04)
- Postoperative complications apart from
intra-abdominal collection (NR/0.13)
- Intra-abdominal collection (NR/0.05)
- Mortality (NR/NR)
Tsai et al. [32], 2010 795 (689/106) > <30 - Blood loss (NR/<0.01)
- Decreased risk of uncinate/retroperitoneal
Margin (NR/0.03)
- Less preoperative weight loss (0.03)
- Pancreatic ﬁstula (0.01)
- Decreased risk of disease speciﬁc
death (<0.01)
- Pancreatic texture (NR/0.2)
- Operative time (NR/0.07)
- Harvested LN (NR/0.08)
- TNM staging (NR/0.34)
- Tumor size (NR/0.5)
- LN metastasis (NR/0.9)
- R1 resection (NR/0.1)
- Tumor differentiation (NR/0.043)
- Hospital stay (NR/0.67)
- Microvascular invasion (0.06)
- Perineural invasion (0.31)
- Perioperative mortality (0.34)
- Overall morbidity (0.4)
- Wound infection (0.2)
Benns et al. [29], 2009 306 (238/68) > <30 - Blood loss (NR/0.007)
- Postoperative complications (NR/0.01)
- Operative time (NR)
- Hospital stay (NR)
- Positive lymph nodes (NR/0.06)
- Tumor size (NR/0.09)
- Recurrence (NR/0.5)
- Overall survival (NR/0.49)
Balentine et al. [38], 2011 200 (147/53) > <30 NO - Postoperative complication (NR)
- Fistula (NR)
- Wound infection (NR)
- Pneumonia (NR)
- Urinary tract infection (NR)
- GI bleeding (NR)
- Abscess (NR)
Dandona et al. [37], 2011 355 (280/55) > <30 NO - Tumor size (0.911)
- Lymph nodes (0.471)
- Resection margin (0.081)
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weight patients can be justiﬁed by less likelihood of complications
(P ¼ 0.001), more ambulation and rapid recovery from post-
operative ileus, earlier start of oral feeding (P ¼ 0.02) and earlier
drain removal (P ¼ 0.007). That can justify the conﬂicting results
between literature as studies that showed a signiﬁcant association
between obesity and overall complication rate found the same
relation between obesity and the duration of hospital stay and vice
versa [2].
An interesting ﬁnding of this study is that there was no signif-
icant difference regarding tumor biology and pathological charac-
ters between the two groups except that safety inﬁltration was
signiﬁcantly higher in the normal weight in comparison to the
overweight group. Similarity in tumor biology between the two
groups was found by previous studies [17,30,34,35]. Moreover, the
John Hopkins group hypothesized that the decreased incidence of
inﬁltration of uncinate or retroperitoneal margin can be justiﬁed by
the increased fat thickness in this margin [32].
One of the limitations of this study is the retrospective nature
but as mentioned before, we use a prospectively maintained
database for patients undergoing PD since 2000 and it had all
preoperative, intraoperative and postoperative data for each pa-
tient (routine prospective practice). Another limitation of this
study, as in other published studies, is difﬁcult assessment of
original weight in patients who had history of weight loss which is
a common association with pancreatic cancers [18].
5. Conclusion
Overweight patients must not be precluded from undergoing
PD. However, operative techniques and pharmacological prophy-
laxis to decrease POPF should be considered in overweight patients.
Clinicians should be aware of longer operative time, longer hospital
stay and increased complication rate in overweight patients espe-
cially when counseling with them. In most patients, there is no
chance to lose weight before surgery but much attention should be
paid to improve performance status of the patient and control co-
morbidities of obesity especially diabetes.
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